INmune Bio, Inc. (INMB) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
INMB Revenue Growth
INMB Revenue Analysis (2015–2025)
As of May 8, 2026, INmune Bio, Inc. (INMB) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, INMB's 5-year compound annual growth rate (CAGR) stands at +35.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $374,000 in 2022.
When compared to Healthcare sector peers including PRTA (-58.0% YoY), ACAD (+9.9% YoY), and BIIB (+0.4% YoY), INMB has underperformed the peer group in terms of revenue growth. Compare INMB vs PRTA →
INMB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INMBCurrent | $0 | -100.0% | +35.4% | -61738.0% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% |
INMB Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $50K | +257.1% | $50K | 100.0% | $-30,869,000 | -61738.0% |
| 2024 | $14K | -91.0% | $14K | 100.0% | $-42,635,000 | -304535.7% |
| 2023 | $155K | -58.6% | $155K | 100.0% | $-29,741,000 | -19187.7% |
| 2022 | $374K | +106.6% | $374K | 100.0% | $-25,951,000 | -6938.8% |
| 2021 | $181K | +1545.5% | $181K | 100.0% | $-29,153,000 | -16106.6% |
| 2020 | $11K | - | $11K | 100.0% | $-12,228,000 | -111163.6% |
| 2019 | $0 | - | $0 | - | $-7,756,001 | - |
| 2018 | $0 | - | $0 | - | $-12,440,000 | - |
| 2017 | $0 | - | $0 | - | $-981,000 | - |
| 2016 | $0 | - | $0 | - | $-227,000 | - |
See INMB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INMB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INMB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINMB — Frequently Asked Questions
Quick answers to the most common questions about buying INMB stock.
Is INMB's revenue growth accelerating or slowing?
INMB revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +35.4%. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is INMB's long-term revenue growth rate?
INmune Bio, Inc.'s 5-year revenue CAGR of +35.4% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is INMB's revenue distributed by segment?
INMB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.